Watertown, Mass., November 04, 2026--Enanta Pharmaceuticals, Inc. Nasdaq Enta , a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, to
Enanta Pharmaceuticals, Inc (ENTA) — Live Session & Technical Brief
Updated Nov 16, 2026 3:10 PM ET · Prev Close $10.99
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-1.82%) in Biotechnology
Enanta Pharmaceuticals, Inc (ENTA) is trading within a tight intraday band at $10.79 (-1.82%, 0.37x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ENTA is trading in line with the S&P 500 (+0.16% alpha). 14-day RSI stands at 43.0, keeping momentum in a bearish regime.
Watertown, Mass., November 04, 2026--Enanta Pharmaceuticals, Inc. Nasdaq Enta , a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, to
Price ($10.79) trades relative to 20-day SMA ($11.18) and 50-day SMA ($11.88).
Market & Sector Relative Strength
ENTA trading in line with the S&P 500 (+0.16% alpha)Recent ENTA Catalyst Headlines
Verified WireWatertown, Mass., October 28, 2026--Enanta Pharmaceuticals, Inc. Nasdaq Enta , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces
Watertown, Mass., October 26, 2026--Enanta Pharmaceuticals, Inc. Nasdaq Enta , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today anno
Watertown, Mass., October 13, 2026--Enanta Pharmaceuticals, Inc. Nasdaq Enta , a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, tod
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $11.18 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (ENTA)
BEARISH MA TRENDRetail & Crowd Sentiment
QuietEnanta Pharmaceuticals announced the first patient dosing in a Phase 1 study for its investigational RNAi therapeutic, Resolve, for the treatment of chronic hepatitis B.
About Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the …
Get Instant ENTA Catalyst Alerts
Receive an email alert when ENTA triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversENTA Session & Catalyst FAQ
Why is ENTA stock trading near flat today?
Enanta Pharmaceuticals, Inc (ENTA) is trading within a tight intraday band at $10.79 (-1.82%, 0.37x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ENTA is trading in line with the S&P 500 (+0.16% alpha). 14-day RSI stands at 43.0, keeping momentum in a bearish regime.
Is ENTA stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.37x relative volume (low participation). Our multi-factor model currently rates ENTA as HOLD. Review full valuation, quality, and timing signals on the ENTA Buy or Sell Decision Brief →
What is ENTA's intrinsic value and expected trading range?
At $10.79, ENTA's modeled 1-to-3 session range is $10.33 – $11.25, with a key inflection level at $11.18 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the ENTA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for ENTA?
RSI at 43.0 reflects soft below-midline momentum. ENTA trades at $10.79 relative to its 20-day SMA ($11.18) and 50-day SMA ($11.88), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.